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Meniere’s disease (MD) is a clinical spectrum of rare disorders characterized by vertigo
attacks, associated with sensorineural hearing loss (SNHL) and tinnitus involving low to
medium frequencies. Although it shows familial aggregation with incomplete phenotypic
forms and variable expressivity, most cases are considered sporadic. The aim of this
study was to investigate the burden for rare variation in SNHL genes in patients with
sporadic MD. We conducted a targeted-sequencing study including SNHL and familial
MD genes in 890 MD patients to compare the frequency of rare variants in cases using
three independent public datasets as controls. Patients with sporadic MD showed a
significant enrichment of missense variants in SNHL genes that was not found in the
controls. The list of genes includes GJB2, USH1G, SLC26A4, ESRRB, and CLDN14. A
rare synonymous variant with unknown significance was found in the MARVELD2 gene
in several unrelated patients with MD. There is a burden of rare variation in certain SNHL
genes in sporadic MD. Furthermore, the interaction of common and rare variants in SNHL
genes may have an additive effect on MD phenotype. This study will contribute to design
a gene panel for the genetic diagnosis of MD.
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INTRODUCTION
Meniere’s disease (MD, MIM 156000) is a chronic disorder of the inner ear characterized by
episodes of vertigo, associated with low to middle frequency sensorineural hearing loss (SNHL),
tinnitus and aural fullness (Lopez-Escamez et al., 2015). The disorder produces an accumulation
of endolymph in the membranous labyrinth, and it may affect both ears in 25–40% of patients
(termed bilateral MD) and most of cases are considered sporadic (Paparella and Griebie, 1984).
However, heterogeneity in the phenotype is observed and some patients may have co-morbid
conditions such as migraine or systemic autoimmune disorders (Gazquez et al., 2011; Caulley
et al., 2017). This phenotypic spectrum can make the clinical diagnosis challenging considering
that some of the symptoms overlap with other vestibular disorders such vestibular migraine (VM)
or autoimmune inner ear disease (AIED) (Hietikko et al., 2011; Lempert et al., 2012; Mijovic et al.,
2013; Requena et al., 2014b).
Epidemiological evidence showing a genetic contribution inMD is based on familial aggregation
studies with a high siblings recurrence risk ratio (λs = 16–48) (Requena et al., 2014a) and the
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description of multiple familial cases in European and Asian
descendant populations (Arweiler-Harbeck et al., 2011; Hietikko
et al., 2013). Exome sequencing has identified private variants
in the FAM136A, DTNA, PRKCB, SEMA3D, and DPT genes in
4 families with autosomal dominant MD, showing incomplete
penetrance and variable expressivity (Requena et al., 2015;
Martín-Sierra et al., 2016, 2017). Moreover, some relatives in
familial MD show partial syndromes, either with SNHL or
episodic vertigo, increasing the granularity in the phenotype in a
given family. However, the genetic contribution of familial genes
in sporadic cases has not been investigated and the occurrence
of recessive and novel variants is not known. More than 110
genes and ≈6,000 variants have been related to hereditary non-
syndromic hearing loss, making gene sequencing panels an
essential tool for genetic diagnosis of hearing loss (TheMolecular
Otolaryngology and Renal Research Laboratories, The University
of Iowa, 0000; Sloan-Heggen et al., 2016). Those genes include
45 genes associated to autosomal dominant SNHL and 71 genes
related to recessive hearing loss (Shearer et al., 1999; Van Camp
and Smith, 2018).
Targeted gene sequencing panels have been demonstrated to
be an excellent tool for molecular diagnosis of rare variants
in known genes with allelic heterogeneity (Brownstein et al.,
2011; Lionel et al., 2018), as well as in sporadic cases of hearing
impairment in specific populations (Gu et al., 2015; Dallol et al.,
2016). So, we selected SNHL genes and designed a custom gene
panel to search for rare and novel variants in sporadic MD.
In the present study, we describe the genetic variation found in
a custom exon-sequencing panel of 69 genes in a large cohort of
MD sporadic cases. We report that certain genes such as GJB2,
USH1G, SLC26A4, and CLDN14 show an excess of missense
variants in sporadic MD cases when compared to controls in the
Iberian population, suggesting that several rare variants in these
genes may contribute to the SNHL phenotype in sporadic MD.
MATERIALS AND METHODS
Editorial Policies and Ethical
Considerations
This study protocol was approved by the Institutional Review
Board for Clinical Research (MS/2014/02), and a written
informed consent to donate biological samples was obtained
from all subjects.
Sample Selection
A total of 890 Spanish and Portuguese patients with MD
were recruited. All patients were diagnosed by neurotology
experienced clinicians from the Meniere’s Disease Consortium
(MeDiC), according to the diagnostic criteria for MD formulated
by the International Classification Committee for Vestibular
Disorders of the Barany Society in 2015 (Lopez-Escamez et al.,
2015). Among them, 830 were considered sporadic MD cases
while 60 were familial MD cases. Details from the selected cases
are described in Table 1. As controls, 40 healthy individuals were
selected from the same population.
TABLE 1 | Participant subjects in this study.
Diagnosed N Sex % Location N
SMD 830 Male 40 North 500
South 320
FMD 60 Female 60 Center 90
Control 40 Portugal 20
Number of individuals and geographical distribution of the selected cases and
controls for targeted-gene sequencing. SMD, sporadic Meniere disease; FMD, familial
Meniere disease.
Selection of Target Genes
Target genes were selected from a literature search attending
to human phenotype (hearing profile, comorbid vestibular
symptoms) and phenotype observations in mouse and zebrafish
models. Most of them were selected from HearingLoss.org
website gene list for monogenic SNHL. Additional genes were
added because they have been previously found in familial MD
(Requena et al., 2015; Martín-Sierra et al., 2016, 2017), or allelic
variations associated with hearing outcome in MD had been
described, such as NFKB1 or TLR10 genes (Requena et al., 2013;
Cabrera et al., 2014). Mitochondrial genes were added since
maternal inheritance is suspected in several families with MD
(Requena et al., 2014b). Relevant information about the location,
size, bibliography, and other characteristics about each gene
included in the panel is presented in Tables S1, S2.
The custom panel (Panel ID: 39351-1430751809) were
designed by the Suredesign webtool (Agilent) to cover the
exons and 50 bp in the flanking regions (5
′
and 3
′
UTR).
This allowed the sequencing around 533.380 kb with more than
98.46% coverage.
Sample Pooling
Enrichment technology allows the selective amplification of
targeted sequences and DNA sample pooling, reducing the costs
of reagents and increasing sample size. We decided to pool
patient samples according to their geographical origin. Each pool
consisted of 10 DNA samples from the same hospital for a total
of 93 pools (930 samples).
DNA concentration and quality were measured on each
sample using two methods: Qubit dsDNA BR Assay kit
(TermoFisher Scientific) and Nanodrop 2000C (ThermoFisher
Scientific). All samples had quality ratios ranging 1.8 and 2.0 in
280/260 and 1.6 to 2.0 in 260/230.
Libraries Preparation Protocol
The HaloPlex Target Enrichment System (Agilent, Santa Clara,
CA) was used to prepare the DNA libraries, according to
the manufacturer protocol. Validation of the protocol and
library performance was analyzed with a 2,100 Bioanalyzer
High Sensitivity DNA Assay kit. Expected concentrations were
between 1 and 10 ng/ul. Higher concentrations than 10 ng/ul
were diluted 1:10 in 10mM TRIS, 1mM EDTA. Targeted-
sequencing was performed in an Illumina Nextseq500 platform.
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Data Generation Pipelines
Raw data downloaded and sequencing adapters were trimmed
following manufacturer indications. The requested depth of
coverage for the sequencing panel was 250X. The minimum
coverage considered was 30X mean depth for nuclear genes,
however mitochondrial sequences reached higher coverages
with the enrichment technology. Bioinformatic analyses were
performed according to the Good Practices recommended
by Genome Analysis ToolKit (https://software.broadinstitute.
org/gatk/). Mitochondrial genes were analyzed using the
same pipeline.
Two methods were used to find differences in how
UnifiedGenotyper and HaplotypeCaller (the old and the most
recent tools for variant calling in GATK suite) address
sequenced pools. Both custom pipelines use BWA-mem aligner
and GATK suite tools following the GATK protocol for
Variant Calling against GRCh37/hg19 human reference genome.
Left normalization for multi-allelic variants were addressed
by separated. Calling was made in the first pipeline with
UnifiedGenotyper modifying number of chromosomes per
sample (per pool, there are 20 chromosomes). The second
pipeline used HaplotypeCaller, which cannot allow the same
approach, but can automatically address high number of calls
with a different approach. Variants with read depth (RD) <10
and genotype quality (GQ) <20 were excluded in all the
calling pipelines following recommended hard filtering steps by
GATK suite.
A third caller tool, VarScan, was used to filter and annotate
quality strand data per variant to compare its output with
GATK-based callers. VarScan allows the variant filtering using
the information obtained according to each strand polarity. The
method retrieves those variants that were only called in one
strand, but not in the reverse strand, leading to false positive calls.
This step was used as internal quality control to avoid strand bias
usually generated in Haloplex data, as it has been reported in
other studies (Collet et al., 2015).
Positive Control SNV Validation
Positive control testing was addressed using samples from
patients with familial MD with known variants on certain genes.
These individuals come from previous familial studies with
independently validated variants by Sanger sequencing. Known
variants were also sequenced and validated by Sanger (Table S3).
Coverage andmapping quality after each pipeline were annotated
and measured. Representative chromatographs from validated
SNVs are detailed in Figure S1.
Selection and Prioritization of Pathogenic
SNV
In order to obtain more information of each SNV, we annotated
the merged files using the ANNOVAR tool. Minor allele
frequencies (MAF) were retrieved for each candidate variant
from gnomAD and ExAC database (total individuals and
non-Finnish European (NFE) individuals). Since the estimated
prevalence of sporadic MD in Spain is 0.75/1,000 individuals
(Morales Angulo et al., 2003), we selected variants with MAF
<0.001 for single rare variant analysis and prioritized them
according to Combined Annotation Dependent Depletion
FIGURE 1 | Flowchart of the bioinformatic analysis. On the left branch, rare variant analysis and priorization workflow. On the right branch, burden analysis of selected
variants.
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(CADD) phred score. For burden analysis of common and rare
variants, we chose a higher MAF value <0.1. The Collaborative
Spanish Variant Server (CVCS) database including 1,644
unrelated individuals was also used for annotation of exonic
rare variants and to retrieve MAF in Spanish population
(dataset fully accessible from http://csvs.babelomics.org/)
(Dopazo et al., 2016).
KGGseq suite (grass.cgs.hku.hk/limx/kggseq) was used for
the selection of rare variants to prioritize the most pathogenic
variants according to the integratedmodel trained algorithmwith
known pathogenic variants and neutral control variants.
Enrichment analysis for each gene was made with all
the exonic variants found with a MAF <0.1. This analysis
required to divide the total amount of variants into three
groups: those described in global ExAC population, those
found in NFE population, and finally those included in CVCS
Spanish population. These three reference datasets were used for
enrichment analysis comparison.
Validation of Candidate Pathogenic SNV
Candidate SNV were visually revised in the BAM files using
Integrative Genomics Viewer (https://software.broadinstitute.
org/software/igv/) and validated in the different pools where they
were called using Sanger sequencing.
Population Statistics
Statistical analysis was performed with IBM SPSS v.20 program,
Microsoft Excel suite tools, and diverse python and java
encoded public scripts. Due to the overrepresentation of Spanish
population in our dataset, most of the selected variants were
filtered through exome sequencing data from Spanish controls
of CSVS database. The MAF was calculated for each variant
in our dataset and rare and previously unreported variants on
MD patients were identified in our gene panel. Odd ratios
with 95% confidence interval were calculated for each variant
using MAF obtained from Spanish population (N = 1,579),
ExAC (N = 60,706), and ExAC NFE (N = 33,370) populations
as controls.
Gene burden analysis was addressed using 2 × 2 contingency
tables counting total exonic alternate allele counts per gene
in our cases against total and NFE controls in ExAC and
CSVS controls. Odds ratios with 95% confidence intervals were
calculated using Fisher’s exact test and obtaining one-sided p-
values. P-values were also corrected for multiple testing by
the total amount of variants found for each gene following
Bonferroni approach.
Position of Variants in Significant Enriched
Genes
Several models were generated for rare variant-enriched domains
in significant enriched genes by using the INSIDER modeling
tool (Meyer et al., 2018). The selected variants per gene are
detailed in results. Prediction values were annotated with their
calculated p values.
RESULTS
Single Rare Variant Analysis
We achieved an average capture efficiency rate (percentage
of total on-target reads in total sequenced reads) of 69% on
the target regions above 30X (minimum depth considered for
quality filtering). The mean coverage percentage can be found in
Table S4. A total of 2,770 SNV in nuclear genes were selected
from the raw merged dataset (18,961 SNVs) after filtering
by quality controls. The analysis workflow is summarized in
Figure 1. For rare variants analysis, SNV that were found inmore
than one pool were selected, remaining 1,239 variants. After that,
we filtered by variants observed in the control pools, leaving
only 392 exonic SNV in cases (278 missense, 111 synonymous,
2 stopgain, and 1 stoploss).
A final set of 162 SNV with a MAF<0.001 were retrieved (143
missense, 18 synonymous, 1 stoploss, 1 stopgain). All the exonic
variants were annotated and scored using different priorization
tools. Of them, 136 SNVs were not previously described in
any population database and we considered them as potential
novel variants.
After prioritizing the exonic variants by CADD phred, 31
rare variants remained (Table 2). Six of them were validated by
Sanger sequencing in more than two individuals in the following
genes: GJB2, ESRRB, USH1G, SLC26A4 (Table S3). The rest of
the variants were considered benign or likely benign since they
did not reach the pathogenicity threshold predicted for KGGSeq.
However, a novel synonymous variant in the MARVELD2 gene
was found and validated in three unrelated individuals.
The minor allelic frequencies in SNV of the 24 mitochondrial
genes included in the panel were compared with the reference
data obtained from MITOmap through its automated mtDNA
sequence analysis system Mitomaster (Ruiz-Pesini et al., 2007).
However, the candidate variants observed do not belong to the
genes targeted in the mitochondrial genome, since they were
not validated by Sanger sequencing. We did not found any SNV
associated with MD (data not shown).
Gene Burden Analysis
To analyse the interaction of multiple variants, we considered
SNV with a MAF<0.1 for the gene burden analysis. A total of
957 exonic variants were retrieved and their frequencies were
compared with the global and NFE frequencies from ExAC, and
with the Spanish population frequencies from CSVS.
A gene burden analysis using our gene set was performed
using these three reference datasets. After Bonferroni correction,
some genes showed a significant enrichment of rare variants
in the three comparisons, making them candidate genes to be
selected for a diagnosis panel for MD (Table 3). Moreover, 6
genes (FAM136A, ADD1, SLC12A2, POU4F3, RDX, and PRKCB)
presented some novel variants that were validated by Sanger, but
they have not been described in global ExAC or CSVS datasets.
Although these previously unreported variants could not be
sequenced in all the parents of these patients, we considered them
as potential de novo variants.
A second variant analysis using the missense variants
described in CSVS Spanish population database was made
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TABLE 2 | Prioritized rare SNVs found in the single rare variant analysis for sporadic MD cases.
Chr. Position Ref Alt Gene Exonic function dbSNP ExAC MAF gnomAD MAF Cohort MAF CADD phred score
chr1 6,488,328 C T ESPN Non-synonymous rs143577178 0.0005 0.0005 0.004819 35
chr4 6,303,574 G T WFS1 Synonymous – – 0.016867 –
chr4 6,303,946 C A WFS1 Non-synonymous – – 0.004819 22.1
chr4 6,304,133 G C WFS1 Non-synonymous 4.08E-06 0.010843 21
chr4 38,775,706 G T TLR10 Non-synonymous – – 0.003614 20.7
chr4 38,776,070 C A TLR10 Non-synonymous – – 0.024096 14.27
chr5 68,715,821 G T MARVELD2 Non-synonymous – – 0.003614 23.3
chr7 107,336,408 A C SLC26A4 Non-synonymous rs200511789 0.0004 0.0004 0.003614 24.3
chr10 14,563,299 G T FAM107B Non-synonymous – – 0.003614 24.9
chr11 76,885,923 G A MYO7A Non-synonymous rs781991817 0.0002 0.0003 0.004819 34
chr11 76,892,617 G C MYO7A Non-synonymous rs200641606 0.0007 0.0007 0.003614 25.5
chr12 65,672,602 C T MSRB3 Synonymous rs149757878 0.0002 0.0005 0.004819 -
chr13 20,763,612 C A GJB2 Non-synonymous rs72474224 – – 0.007229 23.8
chr14 76,957,891 G A ESRRB Non-synonymous rs201344770 0.0003 0.0002 0.008434 23.8
chr14 76,966,336 G A ESRRB Non-synonymous rs200237229 0.0007 0.0005 0.003614 1.198
chr14 76,966,347 C T ESRRB Non-synonymous rs201448899 0.001 0.0007 0.008434 15.41
chr16 24,046,852 C T PRKCB Synonymous rs115645964 0.0003 0.0003 0.003614 -
chr17 72,915,919 C T USH1G Non-synonymous rs151242039 0.0006 0.0008 0.003614 8.91
chr17 72,916,543 T G USH1G Non-synonymous – – 0.004819 14.31
chr17 79,478,028 G A ACTG1 Synonymous rs187127467 0.0002 0.0003 0.008434 -
chr18 32,462,094 G T DTNA Non-synonymous rs533568822 2.47E-05 3.66E-05 0.003614 25
chr19 50,784,974 A C MYH14 Non-synonymous – – 0.003614 20.3
chr22 38,119,197 G T TRIOBP Non-synonymous – – 0.003614 17.9
chr22 38,119,969 C A TRIOBP Non-synonymous – - 0.010843 15
chr22 38,119,977 G T TRIOBP Non-synonymous – – 0.003614 0.022
chr22 38,120,106 A C TRIOBP Non-synonymous – – 0.003614 2.968
chr22 38,120,116 C A TRIOBP Non-synonymous – – 0.024096 16.55
chr22 38,120,263 C A TRIOBP Non-synonymous - - 0.020482 22.3
chr22 38,120,302 C A TRIOBP Non-synonymous – - 0.003614 23.8
chr22 38,168,691 G C TRIOBP Non-synonymous rs373236761 0.0001 0.0002 0.003614 26.6
Minor allele frequency for each SNV is detailed as annotated by ExAC and gnomAD (exomes). Pathogenicity prediction is detailed according to CADD phred score.
(Table 4). Eighteen genes showed an excess of missense variants
(a total of 46 variants, detailed in Table S5). Of note, five
genes causing autosomal recessive SNHL showed the highest
accumulation of missense variants when they were compared
with NFE and Spanish population datasets: SLC26A4, GJB2,
CLDN14, ESRRB, and USH1G. The variants in these five
genes were validated through Sanger sequencing and considered
Spanish population-specific variants.
Excess of Rare Variants in Hearing Loss
Genes in Familial Cases
We used exome sequencing datasets from familial MD cases
previously reported to search for rare variants identified in our
panel in the sporadic cases. Although no single missense variant
was found segregated in all the cases in the same family, we
found several rare missense variants in at least one case per family
in genes such as GJB2, GRHL2, TRIOBP, RDX, KCNQ4, WFS1,
and ADD1. These MD families show phenotypic differences in
terms of age of onset, hearing profile and disease progression
and the presence of rare variants can be addressed as potential
modulators of the phenotype in each familial case (Table 5).
Effect of Rare Variant Interaction
We selected exonic variants from the gene burden analysis to
analyze their potential additive effect at the protein-protein
interaction interfaces by the tool INSIDER for our selected
five genes. However, protein interfaces for ESRRB, CLDN14
and SLC26A4 genes could not be loaded and processed on the
database (lacking predicted interfaces on ÉCLAIR database
or crystalized protein structures on Protein Data Bank (PDB)
database). Of note, most relevant affected interaction is observed
in the self-interaction GJB2-GJB2 by the known variants
observed in the burden analysis (significant spatial clustering
with 4 SNV, p = 0.0009) rs111033218:G>C (p.Phe83Leu),
rs80338945:A>G(p.Leu90Pro), rs374625633:T>C(p.Ile30Val),
and rs2274084:C>T(p.Val27Ile) (Figure 2A).
Other interactions of interest were founded between the
USH1G—USH1C genes, but the involved variants were not
located in the known interaction surface of USH1G (Figure 2B).
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TABLE 5 | Missense variants found in familial MD cases.
Cases Family SNV Gene RefSeq Described in Pathogenicity MAF
(gnomAD)
MAF
(ExAC)
All 1 chr2:70527974 G>A FAM136A NM_032822.2 (Requena et al., 2015) Pathogenic
1 1 chr4:6303197 G>A WFS1 NM_006005.3 No Conflicting
interpretations of
pathogenicity
0.0041 0.0045
2 1 chr13:20763264 C>T GJB2 NM_004004.5 No Benign/likely benign 0.0094 0.0106
All 1 chr18:32462094 G>T DTNA NM_001198938.1 (Requena et al., 2015) Likely pathogenic 3.66E-05 2.47E-05
2 2 chr1:41296865 G>A KCNQ4 NM_004700.3 No Unknown significance 2.13E-05 3.49E-05
All 2 chr1:168665849 G>A DPT NM_001937.4 (Martín-Sierra et al., 2017) Likely pathogenic 2.03E-05 2.5E-05
2 2 chr4:2900221 A>G ADD1 NM_014189.3 No Unknown significance 8.12E-06 8.24E-06
All 3 chr7:84642128 C>T SEMA3D NM_152754.2 (Martín-Sierra et al., 2017) Pathogenic
All 3 chr8:102555482 G>T GRHL2 NM_024915.3 No Unknown significance
All 4 chr16:23999898 G>T PRKCB NM_002738.6 Martín-Sierra et al., 2016 Pathogenic
1 4 chr22:38119405 C>T TRIOBP NM_001039141.2 No Likely benign 4.06E-05 2.49E-05
1 4 chr3:191098660 A>G CCDC50 NM_178335.2 No Benign 0.0061 0.0065
1 4 chr11:110134833 T>C RDX NM_002906.3 No Unknown significance
Variants were retrieved from familial cases segregating a partial phenotype in different families.
FIGURE 2 | Representation of domains and interactive interface in GJB2—GJB2 (A) and USH1G—USH1C (B) interaction. Marked in darker color boxes, interactive
surfaces of the protein. Aminoacids in the interactive surface of the protein are highlighted in the same color. Variants that affect the interaction regions between both
proteins are marked in red and yellow. Only in GJB2—GJB2 self-interaction missense mutations are relevant in the interaction (dbSNP ids detailed in black). The rest
of the variants affecting aminoacids tested in both interactions that are out in the interactive surface region are marked in pink.
To assess if the SNHL genes showing enrichment of
missense variants were located in genomic regions with a higher
recombination rates, we retrieved recombination rates from
deCODE genetics maps for the ESRRB, GJB2, USH1G, CLDN14,
and SLC26A4 genes and calculated linkage disequilibrium
correlations for candidate missense variants in these five genes.
USH1G and ESRRB genes have the highest recombination
rates and they seem to be in genomic regions considered
as hotspots (Table S6). However, most of the rare missense
variants found were not clustered and showed a scattered
distribution along the different exons with a low recombination
rate (Table S7).
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DISCUSSION
This study shows that patients with sporadic MD have an
enrichment of few rare variants in certain hearing loss genes such
as GJB2, SLC26A, or USH1G. This excess of missense variants
in some genes may increase the risk to develop hearing loss in
MD and may contribute to explain the heterogeneity observed
in the phenotype (Francioli et al., 2015). To understand the
relevance of population frequencies in our cohort, we performed
the association analysis between variants observed in MD cases
against their respective frequencies on a healthy population for
each gene of the panel (Lek et al., 2016). From the total amount
of variants, we selected rare coding variants for all the targeted
genes. We applied a stronger filter for the selection of missense
variants by choosing previously described variants for each gene
significantly overrepresented in MD cases.
Since many missense variants were not found in the Spanish
population from CSVS (Dopazo et al., 2016), a third comparison
limited to previously reported variants in CSVS database was
carried out. We followed this conservative approach to reduce
false positive findings in the readings. This third restrictive gene
analysis was limited to 132 variants observed at least once in the
Spanish reference population.
From the final analysis, we found that some genes such
as SLC26A4, ESRRB, CLDN14, GJB2, and USH1G retained
the higher number of missense variants among Spanish MD
patients. We also found one novel synonymous variant in the
MARVELD2 gene in 3 unrelated patients. Besides from its
functional implications, it may also generate a cryptic splice site.
However, more testing is needed to confirm this finding.
Multiallelic Model for MD
The excess of missense variants in SNHL genes may point to core
gene for hearing loss in MD. Our hypothesis is that common cis-
regulatory variants and rare variants in one or more genes will
contribute to the phenotype in MD. The model will need the
additive effect of at least a common and a rare variant in the same
gene in a given individual (Castel et al., 2018). In the simplest
bi-allelic hypothesis, we will have:
Ind 1 = cv a + rv z (geneA)
Ind 2 = cv b + rv y (geneB)
Ind 3 = cv a + rv x (geneA)
Ind 4 = cv b + rv w (geneB)
Where cv is a common variant and rv represents a rare variant;
however, this model could be more complex for a single gene:
Ind 1 = cv a + cv c + rv z (geneA)
Ind 2 = cv b + cv d + rv z (geneB)
So, several rare variants will be targeting the core genes (rv z,
rv x for gene A; rv y, rv w for gene B) and common variants
in the same genes will explain variable expressivity of the MD
phenotype. Finally, in a more complex scenario, it could involve
several genes (oligogenic multiallelic hypothesis):
Ind n = cv a+ rv z
(
gene A
)
+ cv b+ rv y
(
gene B
)
+ . . .+ cv n+ rv m (gene N)
Gene Panel for Familial MD
The Genomics England project (https://www.genomicsengland.
co.uk/) has designed gene panels for the diagnosis of many
genetic disorders including familial MD (https://panelapp.
genomicsengland.co.uk/panels/394/). This panel is in an early
stage of development because it only considers 130 genes with
limited evidence to few families. The results of this study can be
used to improve the design of panels for the diagnosis of MD.
For the design of our panel, we chose a total of 69 genes.
Most of the genes were selected according to the hearing loss
profile (low frequency or pantonal hearing loss). However, more
than 90 genes have been related to hearing loss, so more
hearing loss genes could be involved in the phenotype (fully
accessible from Hereditary Hearing Loss Homepage: http://
hereditaryhearingloss.org/). Genetic evidence of hearing loss has
been obtained from linkage analyses until the emergence of NGS
techniques (Shearer et al., 1999), that have facilitated the clinical
development of genetic diagnosis in hearing loss. Custom panels
and microarrays have been the flags of a new age of discovery
of novel and rare variants for genetic diagnostic of hearing loss
(Brownstein et al., 2011; Shearer and Smith, 2015).
Our panel was designed considering hearing loss as the main
symptom shared by all patients with MD, since the vestibular
phenotype and other associated co-morbidities such as migraine
or autoimmune disorders are more variable. To improve the
diagnostic yield of MD and to decrease this granularity in the
phenotype, it will be recommendable to select sporadic patients
with an early age of onset for future studies.
Rare Missense Variants in Hearing Loss
Genes in Sporadic MD
The frequency of hearing loss related genes is population-specific
(Sloan-Heggen et al., 2016). Herein, we present a study for MD
patients in the Spanish population. As a part of the study, we
consider a panel of genes related to hearing loss and other
symptoms. Besides from the validated variants in singletons,
only a few rare variants such as ESRRB rs201448899:C>T,
MARVELD2 rs369265136:G>A, SLC26A4 rs200511789:A>C,
and USH1G rs151242039:C>T have been validated in more than
one sporadic case in the entire cohort. All these genes had been
previously considered as pathogenic for hearing loss, but they
have never been involved with MD.
ESRRB encodes the estrogen-related receptor beta, also known
as nuclear receptor subfamily 3, group B, member 2 or NR3B2.
This gene encodes for a protein like the estrogen receptor but
with a different and unknown role. Mutations in the mouse
ortholog have been involved in the placental development and
autosomal recessive SNHL (Collin et al., 2008;Weber et al., 2014).
MARVELD2 encodes a protein found in the tight junctions,
between epithelial cells. The encoded protein seems to
forge barriers between epithelial cells such the ones in the
organ of Corti, Defects in this gene are associated with
DFNB49 (Mašindová et al., 2015).
SLC26A4 gene encodes pendrin, a protein extensively studied
in hearing loss. Its alteration is one of the most common causes
of syndromic deafness and autosomal recessive SNHL. It is also
associated with enlarged vestibular aqueduct syndrome (EVAS)
[(Yang et al., 2007), 36].
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USH1G is a gene translating to a protein that contains three
ankyrin domains, a class I PDZ-binding motif and a sterile alpha
motif. This protein is well-known to interact with harmonin
(USH1C) in the stereocilia of hair cells, a protein associated with
Usher syndrome type 1C (Weil et al., 2003). This protein plays
a role in the development and maintenance of the auditory and
visual systems and functions in the cohesion of hair bundles
formed by inner ear sensory cells. Alterations in the integrity of
the protein seem to be the cause of Usher syndrome type 1G (Weil
et al., 2003; Miyasaka et al., 2016).
However, ESRRB rs201448899:C>T has been observed in
more Spanish controls than in global or NFE in ExAC. This
increased frequency on the Iberian population when compared
with other known largest frequencies as NFE, suggests that this is
a population specific variant rather than a MD disease variant.
Only the MARVELD2 rs369265136:G>A variant remains as a
proper novel related to MD cases. However, the functional effect
of a synonymous variant is unknown and functional studies will
be required to decipher the relevancy of this variant in MD cases
in the future.
Burden Analysis of Rare Missense Variants
in Sporadic MD
Our results demonstrate a burden of rare missense variants in few
SNHL genes, including GJB2, ESRRB, CLDN14, SLC26A4, and
USH1G. We speculate that the additive effect of several missense
variants in the same gene could interact with the same or other
genes at the protein level resulting in the hearing loss phenotype.
Population analysis was addressed in order to obtain a better
image of our cohort. Despite the limitation that represents the
small number of genes considered in our panel, we have found
a significant increase of missense variants on several hearing loss
genes in the Iberian population (Table 4). These findings suggest
the involvement of multiple missense variants in the same gene
and may explain several clinical findings in MD. So, incomplete
phenotype found in relatives of patients with familial MD or
even the variable expressivity observed could be explained on the
differences found in multiple rare variants with additive effect
among individuals of the same family (Requena et al., 2015;
Martín-Sierra et al., 2016, 2017). In addition, some sporadic cases
where a single rare variant with unknown significance cannot
explain the phenotype could be singletons individuals with low
frequency variants probably following a compound heterozygous
recessive pattern of inheritance. Our results start to decipher the
complex interaction between rare and ultrarare variations (MAF
<0.0001) with common variants in the same or different genes
in sporadic MD, adding more evidence to understand the genetic
architecture of MD. However, one of the limitations of this study
is the lack of availability of a replication cohort with different
ethnicity in which to validate these findings.
Another limitation of our dataset is that the method used for
resequencing mitochondrial genes may not be able to distinguish
mitochondrial from nuclear sequences, as capture panels such
as those based in the Haloplex technology may sequence all
mitochondrial genome fragment replicas that are dispersed
throughout the nuclear genome. Hence, variants observed may
not belong to the genes targeted in the mitochondrial genome,
but to their pseudogenes in the nuclear genome.
Several hypotheses could explain the excess of missense
variants in SNHL genes in MD. First, the variable expressivity
of SNHL in MD phenotype, could be the result of additive
effect of low frequency or rare variants in the same gene. The
combination of low frequency variants in the same gene can
be a rare situation, as rare as the disease. As much changes are
added to the protein, its integrity could be affected, showing a
suboptimal functioning and finally, a loss of function. In our
case, GJB2, that forms a hexamer with a transmembrane channel
function, has been determined as possible affected by these
changes in their interactions. Previous studies have determined
how certain changes in the monomer can affect to the develop
of the hexamer hemichannel (Bicego et al., 2006; Jara et al.,
2012). Here, bioinformatics models show how the interaction
of low frequency variants found in MD patients can impact the
interaction between two connexins monomers, but this effect
could be amplified in a model including the 6 connexins that
form the connexon. However, this hypothesis is difficult to
reconcile with the fact that for some small genes such as GJB2,
complex alleles with several point mutations are exceedingly rare.
A second hypothesis points to the interaction of common and
rare variants in one or several genes in the disease phenotype,
following its complex disease definition (Becker, 2004; Mitchell,
2012). So, the excess of rare variants will be targeting core
genes for hearing loss in MD. In this case, high significant
genes in our study could be added to the panel of candidate
targets of the disease, although a single variant could not be
enough to explain the disease phenotype. So, the interaction
between cis-regulatory variants with rare variant in some of our
candidate genes and other, a priori, not related SNHL genes
could be relevant in the expressivity. USH1G interacts with
USH1C, a known gene involved in Usher syndrome. USH1G
has been observed to have a minor role in Usher syndrome in
Spanish population (Aller et al., 2007), but not in MD, even
though they share similar hearing loss profile. Although no
one of the missense variants in USH1G were in an interaction
domain, this could be of interest when considering interaction
between different proteins as a main factor to develop a mild
phenotype. This hypothesis was reinforced through the data
found in familial cases. For instance, the variant rs748718975
in DPT gene was only associated with the SNHL phenotype
in the family where it was described, but these cases showed
different characteristics in the age of onset or hearing loss
outcome. These differences between the cases can be explained
with other variants found in KCNQ4 (rs574794136:G>A) and
ADD1 (rs372777117:A>G) genes, although these variants were
previously described as variants of unknown significant. So, the
variant rs574794136:G>A was found in two sisters with MD, but
not in the third one, that was carrier of rs372777117:A>G. This
excess of rare variants in certain genes observed in familial cases
could explain the differences in expressivity in a given family.
This panel was made as an early screening diagnostic panel.
Here we have found that certain SNHL gene variants can be
related to MD in the Iberian population and the results show that
multiple rare allelic variants in the same gene should be consider
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as likely pathogenic. Although there are large differences in the
coverage for some genes between the MD panel and the WES
databases, these are not the ones with excess of missense variants.
Our results will contribute to design a novel gene panel for the
genetic diagnosis of MD.
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